Telesis Bio, Inc. (TBIO) Q4 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. And welcome to the Q4 2022 Telesys BioEarnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jen Carroll, TELUSIS Vice President of Investor Relations. You may begin. Thank you, Dustin. Good afternoon, and thanks for joining us for TELUSIS-Bio's fourth quarter and year-end 2022 earnings call. With me on the call today are TELUSIS-Bio founder and Chief Executive Officer Todd Nelson, Chief Operating Officer Eric Esser, and Decky Goodrich, Senior Vice President of Commercial Operations. Our fourth quarter and full year 2022 financial results press release is now available on the Investors section of our website. Before we begin, I would like to inform you that certain statements we make during the call will be forward-looking statements that involve known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such factors include those referenced in the Safe Harbor Statement included in our earnings release and in our filings with the FDC. This conference call contains time-sensitive information, and it's accurate only as of the live broadcast on March 21st, 2023. Finally, any percentage changes we discuss will be on a year-over-year basis unless otherwise noted. And with that, I will hand the call over to our CEO, Seth, and ...